Protocol Ledger

NCT04142749 · Phase III · COMPLETED

Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

Interventional Phase III clinical trial protocol NCT04142749 sponsored by PharmaKing in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-15 Enrollment: 146 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04142749
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04142749
Protocol FieldVerified Registry Value
NCT IdentifierNCT04142749
Consolidated Lead SponsorPharmaKing
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment146 participants (ACTUAL)
Registered Start Date2019-11-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04142749
Hospital Research SiteLocationSite Profile
Inha University HospitalIncheon, South KoreaOpen Hospital Dossier ->
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI